Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Grass Pollen PreparationPfaar O.a · van Twuijver E.c · Hecker H.b · Boot J.D.c · van Ree R.d · Klimek L.a
aCenter for Rhinology and Allergology Wiesbaden, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, and bHAL Allergie GmbH, Düsseldorf, Germany; cHAL Allergy B.V., Leiden, and dDepartment of Experimental Immunology and Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Climatic changes causing early pollen flight and new allergens prolonging the pollen season render up-dosing of allergen-specific subcutaneous immunotherapy (SCIT) outside the pollen season considerably more difficult. In addition, for patients with multiple pollen allergies, patients coming near the beginning of pollen season, and patients who wish to up-dose faster, an accelerated induction regimen would be helpful. Methods: In an open, randomized, parallel group, multicenter safety trial, an accelerated up-dosing regimen (0.1–0.3–0.5 ml in weekly intervals) was compared to conventional up-dosing (0.05–0.1–0.2–0.3–0.4–0.5 ml in weekly intervals) with an allergoid grass pollen SCIT preparation. After up-dosing, the maintenance dose was given in monthly intervals. Results: A total of 146 adult patients with rhinitis or rhinoconjunctivitis with or without mild asthma (FEV1 >70%) due to grass pollen were randomized to either the conventional registered up-dosing or an accelerated regimen. In both groups (accelerated regimen, n = 69; conventional regimen, n = 75), a high proportion of patients (92.75 and 92.0%, respectively) successfully reached the maintenance dose without safety concerns. Furthermore, significant increases in specific IgG and IgG4 after 4 months of treatment were observed in both groups. Conclusion: The accelerated SCIT regimen was found to be as safe as the conventional regimen and might be used to up-dose patients within 2 weeks. Moreover, the immunological effects of both up-dosing regimens were comparable.
© 2012 S. Karger AG, Basel
- Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update [in collaboration with the World Health Organization, GA(2)LEN and AllerGen]. Allergy 2008;63(suppl 86):8–160.
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; CD001936.
- Bousquet J, Michel FB: Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf 1994;10:5–17.
- Grammer LC, Shaughnessy MA, Patterson R: Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397–401.
- Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E: Standards for practical allergen-specific immunotherapy. Allergy 2006;61(suppl 82):1–20.
- Hansen I, Hormann K, Stuck BA, Schneider-Gene S, Mosges R, Klimek L: Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal) (in German). Laryngorhinootologie 2003;82:558–563.
Penas A, Bosque M, Cruz M, Garcia M: Observational study of the safety of an accelerated subcutaneous immuntherapy regimen in a pediatric population. Allergy 2011;66(suppl 94):207.
- Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, Moreno AC et al: Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol 2009;150:102–108.
- Pfaar O, Leitzbach S, Hormann K, Klimek L: Cluster protocols in SCIT: enough evidence for practical use? Curr Opin Allergy Clin Immunol 2010;10:188–193.
- Subiza J, Feliu A, Subiza JL, Uhlig J, Fernandez-Caldas E: Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy 2008;38:987–994.
- Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B et al: Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005;116:109–118.
- Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J: Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 2009;148:161–169.
- Ariano R, Canonica GW, Passalacqua G: Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Ann Allergy Asthma Immunol 2010;104:215–222.
de Weger LA, Hiemstra PS: The effect of climate change on pollen allergy in the Netherlands (in Dutch). Ned Tijdschr Geneeskd 2009;153:A1410.
- Schubert R, Eickmeier O, Garn H, Baer PC, Mueller T, Schulze J, et al: Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol 2009;148:251–260.
- Mellerup MT, Hahn GW, Poulsen LK, Malling H: Safety of allergen-specific immunotherapy: relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000;30:1423–1429.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.